Access to anti-retroviral drugs, male in Congo

Congo: Access to anti-retroviral drugs, male was 40.0% in 2024. ◆ Volatile

Latest (2024)
40.0%
Change on year
up 17.6%
World rank
131st
of 141 countries
All-time high
40.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Congo, 2000–2024

0102030402000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 4 %2006: 5 %2007: 7 %2008: 15 %2009: 18 %2010: 22 %2011: 16 %2012: 18 %2013: 20 %2014: 19 %2015: 20 %2016: 21 %2017: 22 %2018: 23 %2019: 23 %2020: 24 %2021: 30 %2022: 31 %2023: 34 %2024: 40 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Congo stood at 40.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 17.6% on the previous year and up 110.5% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Congo peaked at 40.0% in 2024 and was at its lowest, 0.0%, in 2000.

Congo ranks 131st of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Congo, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Congo, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 4.0%
2006 5.0% +25.0%
2007 7.0% +40.0%
2008 15.0% +114.3%
2009 18.0% +20.0%
2010 22.0% +22.2%
2011 16.0% -27.3%
2012 18.0% +12.5%
2013 20.0% +11.1%
2014 19.0% -5.0%
2015 20.0% +5.3%
2016 21.0% +5.0%
2017 22.0% +4.8%
2018 23.0% +4.5%
2019 23.0% +0.0%
2020 24.0% +4.3%
2021 30.0% +25.0%
2022 31.0% +3.3%
2023 34.0% +9.7%
2024 40.0% +17.6%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.9% 0.0% 18.0% 10
2010s 20.4% 16.0% 23.0% 10
2020s 31.8% 24.0% 40.0% 5

Countries ranked near Congo

  1. 128 Mongolia 42.0% compare
  2. 128 Philippines 42.0% compare
  3. 130 Suriname 41.0% compare
  4. 131 Ghana 40.0% compare
  5. 133 Djibouti 28.0% compare
  6. 133 Fiji 28.0% compare
  7. 133 Tunisia 28.0% compare

See the full ranking of 160 places →

More gender data for Congo

All data for Congo →

Frequently asked questions

What is access to anti-retroviral drugs, male in Congo?
Access to anti-retroviral drugs, male in Congo was 40.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Congo?
The highest recorded value was 40.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Congo?
The lowest recorded value was 0.0% in 2000.
How does Congo rank for access to anti-retroviral drugs, male?
Congo ranks 131st out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Congo?
Over the last ten years it is up 110.5%. The long-run trend across the full record is volatile.
Where does this Congo data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Congo. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/congo-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/congo-rep/">Access to anti-retroviral drugs, male in Congo</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.